Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 17 Sep 2026

AUROPHARMA, full dossier

Aurobindo Pharma announced that it has received final approval to manufacture and market beclomethasone dipropionate hfa inhalation aerosol in the US.

5 publishers have reported this development. Each act of reporting is below, cited.

The record

Aurobindo Pharma announced that it has received final approval to manufacture and market beclomethasone dipropionate hfa inhalation aerosol in the US.

indiatimes.com16 Sep 2026

Aurobindo Pharma announced that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol.

Aurobindo Pharma has received final approval from the US Food and Drug Administration to manufacture and market its first metered-dose inhaler for asthma treatment in the United States.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.